Carlyle Group to acquire Unchained Labs for $435M

By The Science Advisory Board staff writers

April 26, 2021 -- The Carlyle Group will acquire life science tools company Unchained Labs for $435 million. The transaction is expected to close in the second quarter of 2021.

Unchained Labs develops tools used by biopharmaceutical researchers to analyze and characterize large, complex molecules. The company has 170 employees and expects to generate over $75 million in revenue in 2021.

The investment in Unchained Labs, in partnership with Novo Holdings, Canaan Partners, and TPG Biotech, marks Carlyle's commitment to healthcare in which it has invested over $16 billion of equity.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.